ReviewCentral-European journal of immunology2021
The role of periostin in kidney diseases.
Review in Central-European journal of immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- Urinary periostin as a novel non-invasive biomarker for kidney scarring in pediatric vesicoureteral reflux patients.Pediatric nephrology (Berlin, Germany) · 2026Article
- Periostin and KIM-1 as Fibrosis-Related Markers Associated with CKD Stage in Children.International journal of molecular sciences · 2026Article
- Role of serum periostin level as profibrotic marker in conjunction with renal resistivity index and shear wave elastography in predicting renal fibrosis in diabetic nephropathy.BMC nephrology · 2025Article
- Interference of periostin attenuates pathological changes, proinflammatory markers and renal fibrosis in diabetic kidney injury.Genes & genomics · 2023Article
- Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment.Biomedicines · 2023Article
- Periostin as a Biomarker in the Setting of Glomerular Diseases-A Review of the Current Literature.Biomedicines · 2022Review
- Periostin Augments Vascular Smooth Muscle Cell Calcification via β-Catenin Signaling.Biomolecules · 2022Article
- Role of Periostin and Nuclear Factor-κB Interplay in the Development of Diabetic Nephropathy.Cells · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is a multi-symptomatic condition resulting from irreversible functional and structural damage to the kidneys. Therefore, finding a specific and sensitive marker to predict the development and progression of CKD is of great interest. Periostin is a matricellular protein involved in tissue remodeling and wound healing. It is highly expressed in various types of kidney diseases, especially in conditions associated with progressive renal fibrosis, while its expression in healthy kidneys is not significant. Numerous experimental and human adult studies indicate the role of periostin in the pathogenesis of various types of kidney disease, though the mechanism of action of periostin appears to be diverse and varies depending on the conditions. The article summarizes current knowledge on the possible roles of periostin in the pathogenesis of kidney injury and its position as a marker in various human renal pathologies. The studies performed so far indicate the potential of urinary and tissue periostin as a promising biomarker of CKD progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.